Press Room

CPHI India 2024

Start
Sunday, November 24, 2024
End
Thursday, November 28, 2024
Location: Delhi, India
Booth Number: 4.J34 | API Zone
Hovione is present at CPHI India in November 2024, know more about the event and contact us to schedule a meeting

Hovione will be exhibiting at CPHI India, one of the most relevant tradeshows for the pharma industry, bringing together leading professionals from the entire pharmaceutical supply chain to network, learn and conduct vital face-to-face business.

 

The Specialist Integrated CDMO

Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

We look forward to seeing you at CPHI India. Meet our team and learn more about Hovione’s latest technologies and innovations in drug development and how we can support your project.
 

Let's discuss your project together.

schedule a meeting

 

 

Find more about CPHI India

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025